-
-
-
-
M650475-10mgMal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.In VitroEribulin (E7389) is a microtubule targeting agent that
-
M650475-5mgMal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.In VitroEribulin (E7389) is a microtubule targeting agent that
-
M647728-100μgMal-C6-α-Amanitin is a agent-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.Form:SolidIC50&: Target:Daunorubicins/Doxorubicins.
-
M647728-1mgMal-C6-α-Amanitin is a agent-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.Form:SolidIC50&: Target:Daunorubicins/Doxorubicins.
-
M647728-500μgMal-C6-α-Amanitin is a agent-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.Form:SolidIC50&: Target:Daunorubicins/Doxorubicins.
-
M648700-10mgMAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).Form:SolidIC50&: Target:Auristatin.
-
M648700-1mgMAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).Form:SolidIC50&: Target:Auristatin.
-
M648700-5mgMAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).Form:SolidIC50&: Target:Auristatin.
-
M659449-10mgMAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F).Appearance:SolidIC50&: Target:AuristatinBiological Activity:MAL-di-EG-Val-Cit-PAB-MMAF consists